- JP-listed companies
- Financials
- Net income margin (%)
(219A)
Market cap
¥41.9B
P/E ratio
-19.2x
Heartseed develops regenerative heart muscle therapies using iPS cell-derived cardiac spheres to treat severe heart failure patients through medical institutions worldwide.
| Period End | Net income margin (%) (Million JPY) | YoY (%) |
|---|